The 2021 optimal formulary and limited-use list for antiretroviral drugs for children

Overview

The WHO 2021 guideline promotes the use of optimal antiretroviral treatment (ART) regimens in all populations. Though new, more effective and better tolerated options with a higher genetic barrier to resistance are now available for adults, optimized treatment options for children lag significantly behind.

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for infants and children, while giving due consideration to the rapidly evolving treatment landscape and the risks inherent in the uncertain timelines for paediatric drug development.